Bispecific antibodies (BsAb) that target CD3 and CD20 represent a new milestone in the treatment of patients with B-cell non-Hodgkin lymphoma. These drugs have demonstrated remarkable single-agent activity in heavily pretreated patients, and at least three have so far received regulatory approvals in various countries. However, BsAbs can lead to potentially severe toxicity associated with T-cell activation, particularly cytokine release syndrome (CRS). The anticipated widespread use of …